PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer
Status:
Not yet recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
Peritoneum is among the most common sites of metastases in gastric cancer. Systemic
chemotherapy is the current standard for peritoneal carcinomatosis (PC), although, the
treatment results remain extremely poor. Pressurized intraperitoneal aerosol chemotherapy
(PIPAC) is a modern treatment modality for PC, that 1) optimize the drug distribution by
applying an aerosol rather than a liquid solution; and 2) apply increased intraperitoneal
hydrostatic pressure to increase drug penetration to the target. Despite some encouraging
preliminary results for PIPAC efficacy, it is still an investigational treatment.
Furthermore, only very limited data exist for bidirectional treatment, which includes a
combination of systemic chemotherapy and PIPAC. Thus, this study will investigate the
feasibility of PIPAC and systemic chemotherapy combination for gastric cancer patients with
peritoneal metastases.
Phase:
N/A
Details
Lead Sponsor:
Vilnius University
Collaborators:
National Cancer Institute (NCI) Vilnius University Hospital Santaros Klinikos